GlassScriptPhysician profile
Cayce Parker
NPI 1962187278
$2,531.21
in general payments reported to CMS, 2019-2025
26 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $295 · 2024: $1,072 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,531.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $412.80 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $386.52 | 2023-2025 | |
| Pfizer INC. | $221.80 | 2023-2025 | |
| Lilly USA, LLC | $206.27 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $176.37 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Shield Therapeutics INC | $148.33 | 2024-2025 | |
| Exact Sciences Corporation | $125.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $109.45 | 2023-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $73.01 | 2025 | Rexulti |
| Seqirus USA INC | $72.52 | 2024-2025 | Flucelvax, Fluad |
| Sanofi-Aventis U.S. LLC | $67.57 | 2024-2025 | |
| Astellas Pharma US INC | $66.66 | 2024-2025 | Veozah |
| Amgen INC. | $48.55 | 2024-2025 | Krystexxa |
| Noven Therapeutics, LLC | $47.44 | 2024-2025 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $44.41 | 2023-2024 | Quviviq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.35 | 2024 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $39.53 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $39.24 | 2024-2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $37.47 | 2024-2025 | |
| Medtronic, INC. | $33.15 | 2025 | Intellis Adaptivestim |
| Edwards Lifesciences Corporation | $31.30 | 2025 | Sapien 3 Ultra Resilia |
| Vanda Pharmaceuticals INC. | $29.66 | 2025 | Hetlioz, Fanapt |
| Horizon Therapeutics Plc | $24.06 | 2023 | Krystexxa |
| Axsome Therapeutics, INC. | $17.91 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.44 | 2025 | Xifaxan |
| Halozyme INC | $13.09 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cayce Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.